| 2024 |
| 04/25 | 345 | 345 | 342 | 345 | 0% | 5,900 | 43億8553万 | -2.27% |
| 04/24 | 343 | 345 | 340 | 345 | +0.58% | 10,700 | 43億8553万 | -2.54% |
| 04/23 | 344 | 344 | 337 | 343 | +1.48% | 16,000 | 43億6011万 | -3.65% |
| 04/22 | 335 | 338 | 334 | 338 | +1.2% | 57,100 | 42億9655万 | -5.32% |
| 04/19 | 342 | 343 | 329 | 334 | -2.34% | 59,700 | 42億4570万 | -6.96% |
| 04/18 | 338 | 344 | 337 | 342 | +0.29% | 20,500 | 43億4740万 | -5.26% |
| 04/17 | 341 | 343 | 339 | 341 | 0% | 16,200 | 43億3468万 | -5.8% |
| 04/16 | 346 | 346 | 338 | 341 | -1.45% | 47,800 | 43億3468万 | -6.32% |
| 04/15 | 341 | 351 | 333 | 346 | +0.58% | 24,500 | 43億9824万 | -5.46% |
| 04/12 | 341 | 349 | 337 | 344 | +0.58% | 26,500 | 43億7282万 | -6.27% |
| 04/11 | 341 | 345 | 339 | 342 | -0.87% | 46,800 | 43億4740万 | -7.32% |
| 04/10 | 346 | 354 | 345 | 345 | -0.29% | 27,200 | 43億8553万 | -7.01% |
| 04/09 | 344 | 346 | 341 | 346 | +0.58% | 16,800 | 43億9824万 | -6.99% |
| 04/08 | 340 | 344 | 339 | 344 | +1.18% | 9,200 | 43億7282万 | -7.77% |
| 04/05 | 336 | 343 | 328 | 340 | -1.16% | 96,400 | 43億2197万 | -9.33% |
| 04/04 | 350 | 350 | 339 | 344 | -0.29% | 43,600 | 43億7282万 | -8.75% |
| 04/03 | 355 | 355 | 344 | 345 | -3.9% | 114,700 | 43億8553万 | -8.97% |
| 04/02 | 370 | 370 | 359 | 359 | -3.49% | 42,300 | 45億6350万 | -5.77% |
| 04/01 | 381 | 381 | 368 | 372 | -2.36% | 90,300 | 47億2875万 | -2.36% |
| 03/29 | 373 | 381 | 373 | 381 | +2.14% | 12,900 | 48億4315万 | -0.26% |
| 03/28 | 377 | 380 | 373 | 373 | -1.06% | 24,300 | 47億4146万 | -2.1% |
| 03/27 | 373 | 378 | 373 | 377 | +0.53% | 18,500 | 47億9231万 | -1.31% |
| 03/26 | 377 | 378 | 372 | 375 | -0.79% | 37,900 | 47億6688万 | -1.83% |
| 03/25 | 381 | 386 | 377 | 378 | -0.53% | 37,900 | 48億502万 | -1.31% |
| 03/22 | 387 | 387 | 378 | 380 | -1.81% | 20,700 | 48億3044万 | -0.52% |
| 03/21 | 380 | 387 | 378 | 387 | +1.57% | 43,000 | 49億1942万 | +1.31% |
| 03/19 | 375 | 383 | 370 | 381 | +1.33% | 61,800 | 48億4315万 | -0.26% |
| 03/18 | 15:00 Nature誌への当社プログラム医療機器に関連する記事掲載のお知らせ |
| 03/18 | 376 | 381 | 373 | 376 | -0.79% | 19,900 | 47億7959万 | -1.83% |
| 03/15 | 395 | 395 | 375 | 379 | -0.26% | 106,900 | 48億1773万 | -1.3% |
| 03/14 | 15:00 ニプロ株式会社との共同開発契約締結のお知らせ |
| 03/14 | 379 | 381 | 376 | 380 | +0.8% | 25,700 | 48億3044万 | -1.3% |
| 03/13 | 378 | 382 | 376 | 377 | -1.31% | 24,600 | 47億9231万 | -2.58% |
| 03/12 | 383 | 384 | 372 | 382 | -1.04% | 32,700 | 48億5586万 | -1.55% |
| 03/11 | 385 | 393 | 374 | 386 | -1.03% | 71,000 | 49億671万 | -1.03% |
| 03/08 | 395 | 399 | 381 | 390 | +2.9% | 178,200 | 49億5756万 | -0.26% |
| 03/07 | 15:00 国立研究開発法人科学技術振興機構(JST)「産学共創プラットフォーム共同研究推進プログラム」への参画について |
| 03/07 | 389 | 390 | 378 | 379 | -2.57% | 38,600 | 48億1773万 | -3.32% |
| 03/06 | 369 | 395 | 367 | 389 | +5.14% | 54,100 | 49億4485万 | -1.27% |
| 03/05 | 376 | 376 | 367 | 370 | -1.86% | 55,400 | 47億332万 | -6.33% |
| 03/04 | 386 | 389 | 377 | 377 | -2.33% | 120,100 | 47億9231万 | -5.04% |
| 03/01 | 391 | 395 | 386 | 386 | -1.28% | 34,300 | 49億671万 | -3.26% |
| 02/29 | 395 | 398 | 386 | 391 | -1.01% | 53,700 | 49億7027万 | -2.25% |
| 02/28 | 396 | 410 | 392 | 395 | 0% | 114,500 | 50億2112万 | -1.5% |
| 02/27 | 382 | 399 | 381 | 395 | +3.67% | 144,800 | 50億2112万 | -1.74% |
| 02/26 | 390 | 392 | 376 | 381 | -0.26% | 164,700 | 48億4315万 | -5.22% |
| 02/22 | 11:30 PAI-1阻害薬RS5614のニボルマブ無効悪性黒色腫を対象とした第II相医師主導治験の最終結果のお知らせ |
| 02/22 | 376 | 401 | 363 | 382 | +3.52% | 393,400 | 48億5586万 | -5.21% |
| 02/21 | 385 | 385 | 369 | 369 | -5.14% | 38,100 | 46億9061万 | -8.89% |
| 02/20 | 388 | 391 | 379 | 389 | +0.52% | 27,700 | 49億4485万 | -4.42% |
| 02/19 | 381 | 389 | 377 | 387 | +0.52% | 34,100 | 49億1942万 | -5.15% |
| 02/16 | 358 | 386 | 354 | 385 | +5.77% | 76,000 | 48億9400万 | -6.1% |
| 02/15 | 376 | 378 | 355 | 364 | -3.96% | 91,800 | 46億2705万 | -11.44% |
| 02/14 | 379 | 391 | 375 | 379 | -2.07% | 77,000 | 48億1773万 | -8.45% |
| 02/13 | 397 | 398 | 376 | 387 | -3.01% | 166,200 | 49億1942万 | -7.19% |
| 02/09 | 408 | 408 | 397 | 399 | 0% | 44,200 | 50億7196万 | -4.55% |
| 02/08 | 15:00 2024年3月期第3四半期決算短信〔日本基準〕(非連結) |
| 02/08 | 414 | 414 | 387 | 399 | -3.62% | 97,900 | 50億7196万 | -5% |
| 02/07 | 417 | 417 | 411 | 414 | -0.72% | 10,900 | 52億6264万 | -1.66% |
| 02/06 | 11:30 精神症状を伴う月経前症候群⁄月経前不快気分障害患者に対するRS8001(ピリドキサミン)の第II相医師主導治験における最終症例の治療終了のお知らせ |
| 02/06 | 415 | 419 | 413 | 417 | -0.24% | 13,000 | 53億77万 | -0.95% |
| 02/05 | 421 | 421 | 412 | 418 | +0.97% | 27,700 | 53億1349万 | -0.71% |
| 02/02 | 415 | 415 | 410 | 414 | +1.47% | 29,900 | 52億6264万 | -1.66% |
| 02/01 | 418 | 418 | 406 | 408 | -2.39% | 71,100 | 51億8637万 | -2.86% |
| 01/31 | 419 | 421 | 415 | 418 | -1.65% | 19,200 | 53億1349万 | -0.71% |
| 01/30 | 423 | 430 | 419 | 425 | -0.23% | 25,000 | 54億247万 | +1.19% |
| 01/29 | 415 | 428 | 413 | 426 | +2.9% | 74,600 | 54億1518万 | +1.43% |
| 01/26 | 422 | 423 | 412 | 414 | -1.66% | 28,100 | 52億6264万 | -1.43% |
| 01/25 | 426 | 437 | 420 | 421 | +1.2% | 64,900 | 53億5162万 | +0.24% |
| 01/24 | 411 | 419 | 411 | 416 | +0.48% | 15,700 | 52億8806万 | -0.72% |
| 01/23 | 418 | 421 | 414 | 414 | -0.96% | 18,200 | 52億6264万 | -1.19% |
| 01/22 | 406 | 419 | 406 | 418 | +2.2% | 41,300 | 53億1349万 | -0.24% |
| 01/19 | 415 | 419 | 407 | 409 | -1.45% | 25,100 | 51億9908万 | -2.39% |
| 01/18 | 409 | 418 | 409 | 415 | +0.24% | 33,900 | 52億7535万 | -0.95% |
| 01/17 | 424 | 428 | 413 | 414 | -2.13% | 36,000 | 52億6264万 | -1.43% |
| 01/16 | 425 | 434 | 423 | 423 | -1.17% | 43,300 | 53億7704万 | +0.48% |
| 01/15 | 425 | 429 | 420 | 428 | +1.42% | 26,900 | 54億4060万 | +1.42% |
| 01/12 | 424 | 427 | 417 | 422 | -0.71% | 28,200 | 53億6433万 | -0.24% |
| 01/11 | 431 | 431 | 418 | 425 | -1.85% | 68,000 | 54億247万 | 0% |
| 01/10 | 434 | 435 | 428 | 433 | -0.92% | 27,400 | 55億416万 | +1.88% |
| 01/09 | 430 | 440 | 430 | 437 | +1.63% | 59,500 | 55億5501万 | +2.58% |
| 01/05 | 431 | 435 | 424 | 430 | -0.92% | 55,300 | 54億6603万 | +0.7% |
| 01/04 | 428 | 436 | 418 | 434 | 0% | 66,800 | 55億1687万 | +1.64% |
| 2023 |
| 12/29 | 421 | 437 | 420 | 434 | +2.84% | 35,300 | 55億1687万 | +1.4% |
| 12/28 | 405 | 428 | 405 | 422 | +2.43% | 102,500 | 53億6433万 | -1.63% |
| 12/27 | 401 | 414 | 398 | 412 | +1.98% | 68,400 | 52億3722万 | -4.41% |
| 12/26 | 409 | 415 | 402 | 404 | -0.49% | 80,100 | 51億3552万 | -6.7% |
| 12/25 | 420 | 420 | 406 | 406 | -2.17% | 56,800 | 51億6095万 | -6.88% |
| 12/22 | 411 | 420 | 410 | 415 | +0.48% | 42,000 | 52億7535万 | -5.25% |
| 12/21 | 409 | 420 | 409 | 413 | -0.72% | 31,400 | 52億4993万 | -5.92% |
| 12/20 | 418 | 428 | 416 | 416 | -0.95% | 34,000 | 52億8806万 | -5.45% |
| 12/19 | 407 | 420 | 407 | 420 | +2.94% | 42,500 | 53億3891万 | -4.98% |
| 12/18 | 409 | 410 | 402 | 408 | -0.97% | 27,700 | 51億8637万 | -7.9% |
| 12/15 | 406 | 413 | 406 | 412 | +1.23% | 39,100 | 52億3722万 | -7.42% |
| 12/14 | 415 | 425 | 402 | 407 | -1.69% | 75,500 | 51億7366万 | -8.95% |
| 12/13 | 410 | 422 | 409 | 414 | +0.73% | 66,900 | 52億6264万 | -7.8% |
| 12/12 | 427 | 428 | 408 | 411 | -4.2% | 107,500 | 52億2450万 | -8.87% |
| 12/11 | 425 | 433 | 420 | 429 | 0% | 77,000 | 54億5331万 | -5.51% |
| 12/08 | 11:30 東レ・メディカル株式会社との共同開発契約締結のお知らせ |
| 12/08 | 437 | 462 | 426 | 429 | -3.16% | 521,600 | 54億5331万 | -5.71% |
| 12/07 | 450 | 451 | 438 | 443 | -1.56% | 72,400 | 56億3128万 | -3.06% |
| 12/06 | 455 | 460 | 448 | 450 | -1.1% | 43,100 | 57億2026万 | -1.75% |
| 12/05 | 11:45 当社PAI-1阻害薬の新規用途特許(発明の名称:免疫チェックポイント分子の発現抑制剤)登録のお知らせ |
| 12/05 | 452 | 469 | 448 | 455 | 0% | 91,200 | 57億8382万 | -0.87% |
| 12/04 | 448 | 460 | 448 | 455 | +2.94% | 64,300 | 57億8382万 | -1.09% |
| 12/01 | 454 | 454 | 442 | 442 | -2.86% | 30,300 | 56億1857万 | -4.12% |
| 11/30 | 452 | 456 | 441 | 455 | +1.79% | 79,600 | 57億8382万 | -1.52% |
| 11/29 | 447 | 452 | 444 | 447 | +0.22% | 35,600 | 56億8212万 | -3.46% |
